Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23799156 | 1.00 | GRM5 (0.38) | GRM5 | |
| SCHEMBL20987585 | 1.00 | GRM5 (0.38) | GRM5 | |
| SCHEMBL17343037 | 1.00 | GRM5 (0.38) | GRM5 | |
| SCHEMBL22429827 | 1.00 | GRM5 (0.38) | GRM5 | |
| SCHEMBL23799094 | 1.00 | GRM5 (0.38) | GRM5 | |
| SCHEMBL23962130 | 0.88 | GRM5 (0.30) | GRM5 | |
| SCHEMBL24581772 | 0.88 | GRM5 (0.30) | GRM5 | |
| SCHEMBL20226627 | 0.88 | GRM5 (0.30) | GRM5 | |
| SCHEMBL20013003 | 0.88 | GRM5 (0.30) | GRM5 | |
| SCHEMBL23962142 | 0.88 | GRM5 (0.37) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709779-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190000959-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10022435-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022435-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9872900-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872900-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNATX, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160317647-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015501-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
| US-20160317647-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | POLRMT, PDE6C, POLN | GRM5 3621/4885 |
| US-10709779-B2 | Nucleic acid vaccines | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | RNGTT, TRDMT1, RNMT | GRM5 2188/4885 |
| US-10022435-B2 | Nucleic acid vaccines | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | POLM, POLN, POLRMT | GRM5 2781/4885 |
| US-20190000959-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | GRM5 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.